Novel therapeutics for acute ulcerative colitis
Official title: Study of Novel Therapeutics for Acute Remedy of Colitis
Run by Brigham and Women's Hospital · NCT06420492 · Data updated 2026-11-12
This trial tests an oral (and sometimes IV) drug called BRS201 in adults with severe ulcerative colitis who have not improved with standard treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Drugs / interventions | Upadacitinib, Tofacitinib, prednisone |
| Locations | 2 sites (Chestnut Hill, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | September 30, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | June 1, 2027 |
| Registry record updated | October 20, 2025 |
| Trial ID | NCT06420492 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with confirmed ulcerative colitis of at least three months' duration, ≥15 cm colonic involvement, currently experiencing an acute severe flare and who have failed an adequate course of prednisone are the ideal candidates.
✕Probably not a fit
Patients with mild disease, very recent diagnosis, unstable doses of permitted concomitant therapies, or contraindications to the drug or study procedures are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open-label phase 2 pilot testing BRS201 over a 12-week participation period with four weeks of active oral dosing (twice daily) and an optional IV dose. Participants will attend eight on-site visits for safety monitoring, blood draws, and collection of stool and urine samples, and may undergo flexible sigmoidoscopy at baseline and end of treatment. Eligible patients include adults with a confirmed diagnosis of UC for more than three months, extensive colonic involvement (≥15 cm), and an acute severe flare that has not responded to prednisone. Concomitant stable doses of certain biologics or JAK inhibitors are allowed if dosing has been stable for the required lead-in periods.
Why it matters
Potential benefit: If successful, BRS201 could provide a new treatment option to reduce symptoms and induce remission in adults with severe, treatment-refractory ulcerative colitis.
How similar studies have gone: BRS201 itself appears to be a novel agent with limited published clinical data, although other drug classes such as biologics and JAK inhibitors have shown benefit in refractory ulcerative colitis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Severe outpatient or hospitalized for an acute UC flare * Ability to give consent * Patients with a confirmed diagnosis of UC for \> 3 months * History of ≥ 15 cm of colonic involvement as confirmed by colonoscopy * Patients with primary sclerosing cholangitis are eligible to enroll * Patients will have failed 5 days of oral prednisone 30 mg or greater for 5 days and still having a SCCAI of \> 6 * Patients who are taking 20mg or less of oral prednisone and plan to stay at that dose during their participation in the study * Accepted medications: * Anti-TNF agents are permissible if the patient has been taking them for at least 10 weeks and anticipates to maintain a steady for the duration of the study. * Rinvoq (Upadacitinib) is permissible if the subject has been taking this medication for at least 4 weeks and anticipates to maintain a steady dose for the duration of the study. * Xeljanz (Tofacitinib) is permissible if the subject has been taking this medication for at least 4 weeks and anticipates to maintain a steady dose for the duration of the study. * Other biologics are permissible if the subject has been taking the medication for at least 10 weeks and anticipates to maintain a steady dose for the duration of the study Exclusion Criteria: * History of uncontrolled hypertension with systolic BP \> 140 and systolic BP \> 90 * Chronic kidney disease as defined by GFR \<55mL/min * Impaired hepatic function (transaminases elevated \> 2.5 x ULN) unless due to PSC * Evidence of C. difficile (Negative test result within 1 month is acceptable) * Infectious Colitis or drug induced colitis * Crohn's Disease or Indeterminate colitis * Decompensated liver disease * Patients who are pregnant or breastfeeding * Patients who have a confirmed malignancy or cancer within 5 years * Congenital or acquired immunodeficiencies * Other comorbidities including: Diabetes mellitus, systemic lupus * Participation in a therapeutic clinical trial in the preceding 30 days or simultaneously during this trial * Patients with a history or risk of cardiovascular conditions, including arrhythmia, long QT syndrome, congestive heart failure, stroke, or coronary artery disease * Prohibited medications: * Rinvoq (Upadacitinib): Subjects will be excluded from this study if their last dose of this medication was administered within 4 weeks. If subjects have stopped taking this medication and their last dose was administered more than 4 weeks prior to enrollment, they will be eligible for participation. * Xeljanz (Tofacitinib): Subjects will be excluded from this study if their last dose of this medication was administered within 4 weeks. If subjects have stopped taking this medication and their last dose was administered more than 4 weeks prior to enrollment, they will be eligible for participation. * Other Medications: Subjects will be excluded from this study if they stopped taking any other medications for ulcerative colitis within 8 weeks. If subjects have stopped taking the medication and their last dose was more than 8 weeks prior to enrollment, they will be eligible for participation.
Where it's running
-
Brigham and Women's Hospital
Chestnut Hill, Massachusetts, United States Recruiting -
Brigham and Women's Hospital
Chestnut Hill, Massachusetts, United States Not yet recruiting
Study contacts
- Study coordinator: Joshua Korzenik, MD
- Email: jkorzenik@bwh.harvard.edu
- Phone: 617 732-6389
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing a probiotic for mild to moderate ulcerative colitis
This study is testing a new probiotic to see if it can help people with mild to moderate ulcerative colitis feel better and improve their gut health.
-
Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy
This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.
-
A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis
A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.
-
Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults
This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.
-
Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease
This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.
-
High Protein, High Fiber Diet for Ulcerative Colitis
This study tests a high-protein, high-fiber diet to see if it helps people with ulcerative colitis by meeting protein needs and lowering harmful hydrogen sulfide production in the gut.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.